Alimera Sciences, Inc. (ALIM) Financial Analysis & Valuation | Quarter Chart
Alimera Sciences, Inc. (ALIM)
ALIMPrice: $5.54
Fair Value: 🔒
🔒score
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina th... more
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization o... more
Description
Shares
| Market Cap | $301.29M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | US | CEO | Richard S. Eiswirth Jr. |
| IPO Date | 2019-11-04 | CAGR | — |
| Employees | 154 | Website | alimerasciences.com |
| Div. Yield | — | Payout Ratio | -0.06% |
| Buy Back Yield | -0.31% | Total Yield | -0.31% |
ALIM chart loading...
Fundamentals
Technicals
| Enterprise Value | $361.50M | P/E Ratio | 5.28 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 3.73 | P/B Ratio | 3.07 |
| P/CF Ratio | -9.93 | P/FCF Ratio | -3.36 |
| EPS | $1.05 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 69.78% | Gross Margin | 0.76% |
| Operating Margin | -0.02% | Profit Margin | -0.25% |
| ROE | -1.59% | ROA | -0.13% |
| ROCE | -0.01% | Current Ratio | 2.39 |
| Quick Ratio | 2.31 | Cash Ratio | 0.55 |
| Debt/Equity | 1.46 | Interest Coverage | -0.19 |
| Altman Z Score | -1.44 | Piotroski Score | 1 |